Hydronidone capsules for hepatitis B-related liver scarring
Treatments studied
Part of Digestive system, Infections clinical trials.
This study tests a new capsule called hydronidone for people with liver scarring caused by chronic hepatitis B. You must already be on stable hepatitis B treatment and have moderate to advanced scarring.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 70 years old and have had hepatitis B for at least 6 months.
- You have liver scarring (fibrosis) shown by a biopsy, a special liver scan (like FibroScan), or imaging tests.
- You have been taking a stable hepatitis B antiviral medicine (like entecavir, tenofovir) for at least 6 months.
- You do not have serious heart, kidney, or other liver diseases, active tuberculosis, or liver cancer.
- You do not have advanced cirrhosis complications (like fluid in the belly, confusion, or internal bleeding).
- You are willing to use effective birth control and not plan pregnancy for the study period.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how a drug called hydronidone is processed and removed from the body using a very small amount of radioactive labeling. It helps researchers understand how the drug works, so it may lead to better treatments for conditions like liver fibrosis.
This trial tests a long-term treatment called hydronidone for liver scarring (fibrosis) caused by chronic hepatitis B. It aims to see if the treatment can help slow or reverse liver damage in people who are already on antiviral therapy or starting treatment for the first time.
This Phase 3 study tests whether hydronidone capsules can help people with long-term hepatitis B–related liver scarring (fibrosis). It aims to track whether treatment reduces or delays serious liver complications over time.
This trial tests a new medicine called Hydronidone Capsule in healthy people to see how the body processes it and whether it is safe. If you are in good health, you may be able to join this first-in-human study.
This study tests a combination of two drugs—peginterferon alfa-2b and a nucleoside analogue (like tenofovir or entecavir)—to see if they work better together for people with stable, compensated cirrhosis from hepatitis B. It aims to improve liver health and reduce the risk of complications.
This trial tests an injection of stem cells from donated umbilical cords to see if it can help people with advanced liver scarring from hepatitis B. You may be able to join if standard treatments haven’t helped enough and you aren’t able to get a liver transplant.
Hear when a new Chronic Hepatitis B-related Liver Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.